- Home
- DNTH vs TXO Comparison
DNTH vs TXO Comparison
Compare DNTH & TXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- TXO
- Stock Information
- Founded
- DNTH 2015
- TXO 2012
- Country
- DNTH United States
- TXO United States
- Employees
- DNTH N/A
- TXO 189
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- TXO Oil & Gas Production
- Sector
- DNTH Health Care
- TXO Energy
- Exchange
- DNTH Nasdaq
- TXO Nasdaq
- Market Cap
- DNTH 823.1M
- TXO 739.0M
- IPO Year
- DNTH N/A
- TXO 2023
- Fundamental
- Price
- DNTH $20.27
- TXO $18.03
- Analyst Decision
- DNTH Strong Buy
- TXO Strong Buy
- Analyst Count
- DNTH 8
- TXO 2
- Target Price
- DNTH $46.43
- TXO $26.00
- AVG Volume (30 Days)
- DNTH 291.2K
- TXO 70.5K
- Earning Date
- DNTH 11-07-2024
- TXO 11-05-2024
- Dividend Yield
- DNTH N/A
- TXO 13.23%
- EPS Growth
- DNTH N/A
- TXO N/A
- EPS
- DNTH N/A
- TXO N/A
- Revenue
- DNTH $5,366,000.00
- TXO $285,451,000.00
- Revenue This Year
- DNTH $44.94
- TXO N/A
- Revenue Next Year
- DNTH N/A
- TXO $31.77
- P/E Ratio
- DNTH N/A
- TXO N/A
- Revenue Growth
- DNTH 51.41
- TXO N/A
- 52 Week Low
- DNTH $6.58
- TXO $17.20
- 52 Week High
- DNTH $33.77
- TXO $23.56
- Technical
- Relative Strength Index (RSI)
- DNTH 22.81
- TXO 39.44
- Support Level
- DNTH $22.19
- TXO $17.78
- Resistance Level
- DNTH $28.56
- TXO $18.51
- Average True Range (ATR)
- DNTH 2.02
- TXO 0.51
- MACD
- DNTH -0.88
- TXO -0.07
- Stochastic Oscillator
- DNTH 3.38
- TXO 23.24
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About TXO TXO Partners L.P. Common Units Representing Limited Partner Interests
TXO Partners LP is focused on the acquisition, development, optimization and exploitation of oil, natural gas, and natural gas liquid reserves in North America.